294 related articles for article (PubMed ID: 877537)
1. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW
Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537
[TBL] [Abstract][Full Text] [Related]
2. A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540) in the treatment of bronchogenic carcinoma.
Cavalli F; Hasler E; Ryssel HJ; Sonntag RW; Brunner KW
Tumori; 1977; 63(2):169-73. PubMed ID: 898287
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors in the chemotherapy of bronchial cancers].
Alberto P
Schweiz Med Wochenschr; 1974 Feb; 104(8):268-71. PubMed ID: 4360755
[No Abstract] [Full Text] [Related]
4. VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.
Eagan RT; Carr DT; Frytak S; Rubin J; Lee RE
Cancer Treat Rep; 1976 Jul; 60(7):949-51. PubMed ID: 64298
[No Abstract] [Full Text] [Related]
5. [Experiences with VP-16 in combination with cyclophosphamide or adriamycin in the anaplastic, predominantly small cell bronchogenic carcinoma].
Schmieder HA; Jungi WF; Mayr AC; Senn HJ
Schweiz Med Wochenschr; 1979 Jun; 109(22):841-4. PubMed ID: 462156
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy in bronchogenic carcinoma.
Ojala A; Nikkanen VN; Palojoki A; Paloheimo S
Ann Clin Res; 1977 Feb; 9(1):12-4. PubMed ID: 329741
[TBL] [Abstract][Full Text] [Related]
7. Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronchogenic carcinoma.
Lanzotti VJ; Thomas DR; Holoye PY; Boyle LE; Smith TL; Samuels ML
Cancer Treat Rep; 1976 Jan; 60(1):61-8. PubMed ID: 63331
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.
Cohen MH; Broder LE; Fossieck BE; Ihde DC; Minna JD
Cancer Treat Rep; 1977; 61(3):489-90. PubMed ID: 194694
[No Abstract] [Full Text] [Related]
9. Combination chemotherapy with cyclophosphamide, vincristine, methyl-CCNU, and bleomycin in advanced bronchogenic carcinoma: experience with 106 patients.
Samson MK; Baker LH; Fraile RJ; Izbicki RM; Vaitkevicius VK
Cancer Treat Rep; 1977; 61(1):59-64. PubMed ID: 67895
[TBL] [Abstract][Full Text] [Related]
10. Relationship between myelosuppression and chemotherapeutic response in small cell bronchogenic carcinoma.
Holoye PY
Exp Hematol; 1985; 13 Suppl 16():72-9. PubMed ID: 2985416
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with methyl-CCNU (NSC-95441), cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and bleomycin (NSC-125066) in advanced bronchogenic carcinoma.
McMahon LJ; Jones SE; Durie BG; Salmon SE
Cancer Lett; 1975 Nov; 1(2):97-102. PubMed ID: 65213
[TBL] [Abstract][Full Text] [Related]
12. Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristine.
Alberto P; Brunner KW; Martz G; Obrecht J; Sonntag RW
Cancer; 1976 Dec; 38(6):2208-16. PubMed ID: 187313
[TBL] [Abstract][Full Text] [Related]
13. [A phase II study of oral VP-16 in primary lung cancer].
Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma.
Bitran JD; Desser RK; DeMeester TR; Colman M; Evans R; Billings A; Griem M; Rubenstein L; Shapiro C; Golomb HM
Cancer Treat Rep; 1976 Sep; 60(9):1225-30. PubMed ID: 189920
[TBL] [Abstract][Full Text] [Related]
15. Remission rates, survival, and prognostic factors in combination chemotherapy for bronchogenic carcinoma.
Alberto P
Cancer Chemother Rep 3; 1973 Mar; 4(2):199-206. PubMed ID: 4729321
[No Abstract] [Full Text] [Related]
16. VP-16 in combinations for first-line treatment of malignant germ-cell tumors and gestational choriocarcinoma.
Newlands ES
Semin Oncol; 1985 Mar; 12(1 Suppl 2):37-41. PubMed ID: 2579442
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of bronchopulmonary small cell carcinoma with a combination of cyclophosphamide and VP-16].
González Larriba JL; Ordóñez Gallego A; Díaz Pérez MA; García de Paredes ML; Zamora P; Montero García JM
Med Clin (Barc); 1984 May; 82(19):836-9. PubMed ID: 6330470
[No Abstract] [Full Text] [Related]
18. [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
Kado M; Oshima S; Matsui Y; Shimokata K; Hara K; Kanda T; Shima K; Takenaka S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):116-21. PubMed ID: 3002282
[TBL] [Abstract][Full Text] [Related]
19. [Cytostatic therapy of tumors of the lung].
De Marco F; Saviano G; Tenore G
Arch Monaldi; 1974; 29(3-4):326-35. PubMed ID: 4463917
[No Abstract] [Full Text] [Related]
20. Oral VP-16-213 in advanced bronchogenic carcinoma and toxic effects when combined with methotrexate.
Anderson G; Bowyer F; Williams L
Thorax; 1981 Jun; 36(6):462-4. PubMed ID: 7314017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
